David Myles Sells 50,000 Shares of Olema Pharmaceuticals (NASDAQ:OLMA) Stock

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) insider David Myles sold 50,000 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $27.60, for a total transaction of $1,380,000.00. Following the completion of the transaction, the insider directly owned 542,761 shares of the company’s stock, valued at approximately $14,980,203.60. The trade was a 8.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Olema Pharmaceuticals Stock Performance

Olema Pharmaceuticals stock opened at $29.19 on Friday. Olema Pharmaceuticals, Inc. has a fifty-two week low of $2.86 and a fifty-two week high of $36.26. The stock’s 50 day simple moving average is $24.70 and its two-hundred day simple moving average is $13.11. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.03 and a current ratio of 8.03. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of -15.61 and a beta of 1.92.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Monday, November 10th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.05). As a group, analysts expect that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently weighed in on OLMA. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their price objective on shares of Olema Pharmaceuticals from $29.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, November 18th. HC Wainwright lifted their target price on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Piper Sandler assumed coverage on Olema Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “overweight” rating and a $40.00 price target on the stock. Finally, The Goldman Sachs Group raised their price objective on Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Olema Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus price target of $41.00.

Olema Pharmaceuticals News Roundup

Here are the key news stories impacting Olema Pharmaceuticals this week:

• Positive Sentiment: Broker upgrades and higher price targets from multiple firms (Citigroup, Oppenheimer, Piper Sandler, Goldman Sachs) lifted analyst support and raised consensus upside (average target ≈ $41), which likely boosted investor confidence. MarketBeat Analyst Coverage
• Positive Sentiment: Olema published an investor presentation emphasizing its palazestrant (OP‑1250) development strategy and combination plans with CDK4/6 inhibitors — useful context for upcoming data and commercial potential that can support the stock. Investor Presentation
• Neutral Sentiment: Institutional ownership is very high (~91.8%), and a mix of recent modest institutional buys/sells was reported — this large institutional base can amplify moves but is not an immediate directional catalyst. Institutional Holdings
• Negative Sentiment: Significant insider selling was disclosed this week: Shane Kovacs sold 100,000 shares (~$2.87M at $28.73) and additional smaller lots; Director/insider David Myles sold multiple blocks (including 50,000 at ~$27.60 and 10,000 at ~$28.34). Large insider sales (noted ownership percentage drops) can weigh on sentiment even if management retains meaningful stakes. Kovacs SEC Filing Myles SEC Filing

Institutional Investors Weigh In On Olema Pharmaceuticals

Institutional investors have recently made changes to their positions in the company. Paradigm Biocapital Advisors LP increased its position in shares of Olema Pharmaceuticals by 0.4% during the third quarter. Paradigm Biocapital Advisors LP now owns 6,794,172 shares of the company’s stock valued at $66,515,000 after acquiring an additional 30,000 shares in the last quarter. Deep Track Capital LP boosted its stake in Olema Pharmaceuticals by 0.8% during the 3rd quarter. Deep Track Capital LP now owns 3,470,172 shares of the company’s stock valued at $33,973,000 after purchasing an additional 27,339 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Olema Pharmaceuticals by 22.4% in the 2nd quarter. Geode Capital Management LLC now owns 1,326,123 shares of the company’s stock worth $5,650,000 after purchasing an additional 242,997 shares in the last quarter. Candriam S.C.A. raised its stake in shares of Olema Pharmaceuticals by 46.9% in the third quarter. Candriam S.C.A. now owns 1,249,727 shares of the company’s stock worth $12,235,000 after purchasing an additional 399,273 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its stake in shares of Olema Pharmaceuticals by 193.4% in the second quarter. Ameriprise Financial Inc. now owns 1,172,863 shares of the company’s stock worth $4,996,000 after purchasing an additional 773,064 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.